The Ministry of Health, Labor and Welfare (MHLW) on January 14 approved two HIV drugs, MSD’s Pifeltro (doravirine) and ViiV Healthcare’s Dovato (dolutegravir + lamivudine), which are expected to soon join the NHI price list under a fast-track reimbursement scheme…
To read the full story
Related Article
- HIV Med Pifeltro Now Available in Japan: MSD
February 18, 2020
- HIV Meds Dovato, Pifeltro to Join NHI Price List on January 22
January 16, 2020
REGULATORY
- Government Unveils Four-Chapter Outline for 2026 Honebuto
June 26, 2026
- LDP, Ishin Leave Chuikyo Reform to Party Negotiators after Talks Stall
June 26, 2026
- Japan Targets Global-Level Growth for Domestic Patented Drug Market
June 25, 2026
- Paxlovid, Awiqli Braced for NHI Price Cuts after CEAs
June 25, 2026
- Drug Pricing to Be Applied to Oncolys Oncolytic Virus Therapy
June 25, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





